Lisanti Capital Growth LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Posted by George Bondi on May 24th, 2026

Lisanti Capital Growth LLC bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 41,470 shares of the company’s stock, valued at approximately $4,341,000.

Several other hedge funds also recently bought and sold shares of the company. Legato Capital Management LLC acquired a new stake in Palvella Therapeutics in the fourth quarter worth $1,192,000. PSP Research LLC acquired a new stake in Palvella Therapeutics in the fourth quarter worth $532,000. Profund Advisors LLC acquired a new stake in Palvella Therapeutics in the fourth quarter worth $608,000. Baader Bank Aktiengesellschaft acquired a new stake in Palvella Therapeutics in the fourth quarter worth $326,000. Finally, Chung Wu Investment Group LLC raised its holdings in Palvella Therapeutics by 1,200.0% in the fourth quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock worth $272,000 after purchasing an additional 2,400 shares during the period. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on PVLA. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. HC Wainwright increased their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Mizuho increased their price objective on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

View Our Latest Analysis on PVLA

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron bought 2,400 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by insiders.

Palvella Therapeutics Stock Down 1.7%

Shares of PVLA stock opened at $113.99 on Friday. The firm has a fifty day moving average of $121.93 and a 200-day moving average of $105.45. Palvella Therapeutics, Inc. has a 12-month low of $20.20 and a 12-month high of $151.18. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -27.34 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, equities analysts expect that Palvella Therapeutics, Inc. will post -5.43 EPS for the current year.

About Palvella Therapeutics

(Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.